Naltrexone, a medication approved by the FDA more than 30 years ago, can reduce alcohol cravings and help people drink less — yet only about 1% of Americans with alcohol use disorder have ever been prescribed it. That is not a typo. A drug that blocks the brain’s opioid receptors and blunts the rewarding effects of alcohol has been sitting on pharmacy shelves since 1994, and the vast majority of the 29.8 million Americans struggling with problematic drinking have never heard of it. For a dementia care audience, this matters enormously: excessive alcohol use is one of the modifiable risk factors for cognitive decline, and anything that reduces heavy drinking has downstream implications for brain health. The gap between what exists and what gets used is staggering.
In 2022, only 7.6% of people with a past-year alcohol use disorder received any treatment at all, and a mere 2.1% received an evidence-based medication like naltrexone. A 2025 study examining more than 52,000 treatment-eligible emergency department visits found that just 0.5% resulted in a naltrexone prescription. This article examines why naltrexone remains so obscure, how it works, what the real barriers are, and what this means for families already navigating the intersection of alcohol misuse and cognitive health. The story of naltrexone is, at its core, a story about how stigma and outdated treatment models can keep a proven intervention out of reach for decades. Below, we walk through the science, the systemic failures, the practical considerations for patients and caregivers, and what the future might look like if prescribing habits finally start to shift.
Table of Contents
- Why Is a Proven Prescription Drug for Alcoholism Almost Never Prescribed?
- How Naltrexone Works in the Brain and What It Cannot Do
- The Alcohol Crisis and Its Toll on Brain Health
- Oral Naltrexone Versus Vivitrol — Costs, Access, and Practical Tradeoffs
- Why the Medical System Keeps Failing Patients With Alcohol Use Disorder
- What Caregivers and Families Should Know
- Will Prescribing Habits Change?
- Conclusion
- Frequently Asked Questions
Why Is a Proven Prescription Drug for Alcoholism Almost Never Prescribed?
The simplest answer is that most doctors do not think of alcohol use disorder as something they treat with a prescription pad. A combination of poor medical education on addiction, deep cultural stigma, and an entrenched belief that recovery means willpower and abstinence has created a situation where pharmacological tools gather dust. Many clinicians report genuine unfamiliarity with prescribing naltrexone. Some mistakenly believe that patients must first be enrolled in a dedicated addiction treatment program before the medication can be dispensed, which is not the case — any physician with prescribing authority can write the script. The numbers tell the story plainly. Naltrexone use among admissions to U.S.
treatment facilities tripled from 0.53% in 2015 to 1.64% in 2018. That sounds like progress until you realize the starting point was essentially zero and the endpoint is still fewer than two out of every hundred patients walking through the door. Compare this to how aggressively statins are prescribed for heart disease or how SSRIs became standard for depression. Alcohol use disorder kills roughly 95,000 Americans per year according to the CDC, yet the medical system treats it less like a chronic disease and more like a personal failing. For families dealing with a loved one who drinks heavily — particularly an aging parent or spouse already showing signs of cognitive vulnerability — this prescribing gap is not an abstract policy problem. It is a missed opportunity sitting in a medicine cabinet that never got filled.
How Naltrexone Works in the Brain and What It Cannot Do
Naltrexone works by binding to opioid receptors in the brain’s reward circuitry. When someone takes naltrexone and then drinks alcohol, the usual dopamine surge is dampened. The drink still tastes the same, but the internal reward signal — that warm rush, that loosening — is muted. Over time, research shows this leads to reduced cravings, fewer binge episodes, and improved adherence to recovery plans. Extended-release naltrexone combined with psychosocial support has been shown to reduce drinking days by approximately two days per month and heavy drinking days by one to two days per month. One critical distinction sets naltrexone apart from older approaches: it does not require total abstinence. A person can begin taking naltrexone while still drinking, with the goal of gradually reducing consumption.
This is a radical departure from the all-or-nothing framework that dominates most treatment programs, and it makes the medication accessible to people who are not ready to quit entirely but who recognize their drinking is a problem. For caregivers watching a family member’s cognitive function erode alongside worsening alcohol habits, a harm-reduction approach may be more realistic than demanding immediate sobriety. However, naltrexone is not a cure, and it does not work for everyone. It is most effective when paired with some form of counseling or behavioral support. People who take opioid medications for pain management cannot use naltrexone, as it will block those medications and can precipitate withdrawal. And because it targets the opioid system rather than alcohol metabolism directly, its benefits vary — some patients notice a dramatic reduction in the urge to drink, while others experience only modest effects. Setting realistic expectations matters, especially for families who may be desperate for a solution.
The Alcohol Crisis and Its Toll on Brain Health
The scale of alcohol misuse in the United States has worsened considerably over the past two decades, and the consequences for brain health are severe. Alcohol-induced death rates increased 89% between 1999 and 2024, with the sharpest rises among younger adults — a 255% increase among women aged 25 to 34 and a 188% increase among men in the same age group. While some improvement appeared in 2023 and 2024, deaths in early 2025 remain approximately 23% higher than in the same period of 2018. These are not just liver disease numbers. Chronic heavy drinking accelerates brain atrophy, damages white matter, and is now recognized as one of the leading modifiable risk factors for dementia.
The Lancet Commission on dementia prevention identified excessive alcohol consumption as a significant contributor to cognitive decline, particularly when drinking is heavy and sustained over years. Alcohol-related brain damage can mimic Alzheimer’s disease on imaging and cognitive testing, and in some cases, the damage is additive — meaning a person with early Alzheimer’s pathology who also drinks heavily will decline faster than either condition alone would predict. For the nearly 30 million Americans with an active alcohol use disorder, the long-term brain health implications are enormous and largely unaddressed. Consider a 62-year-old man whose family notices increasing forgetfulness and personality changes. A workup might focus on Alzheimer’s or vascular dementia, but if that same man is quietly drinking a bottle of wine every night, no amount of cognitive testing will produce meaningful results until the alcohol problem is addressed. Naltrexone, prescribed by a primary care doctor during a routine visit, could be the intervention that makes the rest of the care plan possible.
Oral Naltrexone Versus Vivitrol — Costs, Access, and Practical Tradeoffs
Naltrexone comes in two forms, and the difference in cost and convenience is significant. The generic oral pill runs roughly $25 to $100 per month without insurance — comparable to many common medications and well within reach for most patients. It is taken daily, which means adherence depends on the patient remembering (or being reminded) to take it. For someone with early cognitive impairment who also has a drinking problem, daily pill compliance can be a genuine challenge, and a caregiver may need to be involved. The alternative is Vivitrol, an extended-release injectable form of naltrexone approved in 2006. Vivitrol is administered once monthly by a healthcare provider, which eliminates the daily adherence problem entirely.
The tradeoff is price: without insurance, Vivitrol costs between $1,200 and $2,500 per month, and no generic version is available. The good news is that an estimated 99% of insurance plans cover Vivitrol, but navigating prior authorizations and finding a provider who administers the injection can still be burdensome. For families already managing complex care schedules for a loved one with dementia, a monthly injection may actually be simpler than adding another daily pill — if the insurance and logistics can be sorted out. Two other FDA-approved medications for alcohol use disorder also exist: disulfiram (sold as Antabuse), which causes nausea and illness if a person drinks while taking it, and acamprosate, which helps stabilize brain chemistry after someone has already stopped drinking. Neither is considered as effective or versatile as naltrexone. Disulfiram relies on a punitive mechanism that many patients simply stop taking, and acamprosate requires abstinence as a starting point. Naltrexone’s ability to work alongside continued (though reduced) drinking makes it the most practical first-line option for most people.
Why the Medical System Keeps Failing Patients With Alcohol Use Disorder
The barriers to naltrexone prescribing are systemic, not incidental. Medical schools have historically devoted very little curriculum time to addiction medicine. A physician who completed training even ten years ago may have received fewer than a handful of hours on alcohol use disorder pharmacotherapy. This is not a knowledge gap that continuing education easily fixes, because the underlying issue is attitudinal: many doctors still view addiction as outside their scope of practice, something best handled by counselors and support groups rather than clinical medicine. Stigma operates on both sides of the exam room. Patients with alcohol use disorder frequently underreport their drinking or avoid raising the subject entirely, fearing judgment.
Doctors, even when aware of naltrexone, may hesitate to bring up alcohol use proactively — particularly with older patients, where the assumption that “they’ve always been a drinker” can normalize dangerous consumption patterns. In dementia care settings, this is especially problematic. Alcohol misuse can be mistaken for sundowning, medication side effects, or progression of cognitive disease, and if nobody asks the right questions, the treatable contributor goes unaddressed. The cultural dominance of abstinence-only models, particularly 12-step programs like Alcoholics Anonymous, also plays a role. AA has helped millions of people, but its framework does not incorporate medication, and some members actively discourage it. When the most visible recovery pathway in American culture treats pharmacology as irrelevant — or even as a crutch — it is unsurprising that both patients and providers overlook what the evidence supports. This is not an argument against AA; it is an argument for expanding the toolkit.
What Caregivers and Families Should Know
If you are caring for someone with both cognitive decline and a drinking problem, you are dealing with one of the more difficult intersections in elder care. Alcohol worsens virtually every aspect of dementia — sleep disruption, fall risk, medication interactions, behavioral symptoms, and the rate of cognitive decline itself. Raising the subject of naltrexone with a loved one’s primary care physician is a concrete step that many caregivers do not know is available to them. A practical approach: bring it up at the next scheduled appointment.
You do not need a referral to an addiction specialist. You do not need to wait for a crisis. Primary care doctors can prescribe naltrexone, and framing the conversation around brain health and fall prevention — rather than labeling someone an alcoholic — can reduce resistance from both the patient and the physician. If the doctor is unfamiliar with naltrexone, the SAMHSA website and NIH treatment guidelines are authoritative resources that can be shared.
Will Prescribing Habits Change?
There are cautious reasons for optimism. The tripling of naltrexone prescribing between 2015 and 2018, while still leaving utilization below 2%, suggests that awareness is growing. Emergency departments, historically the least likely setting for addiction treatment, are beginning to pilot naltrexone prescribing protocols — though the 2025 study showing only 0.5% of eligible ED encounters resulting in a prescription makes clear how far there is to go. Telehealth platforms specializing in addiction medicine have also emerged, making it possible for patients in rural or underserved areas to access prescriptions without an in-person visit. The broader shift toward recognizing alcohol use disorder as a chronic medical condition rather than a moral failure will ultimately determine whether naltrexone reaches the patients who need it.
For the dementia care community, the stakes are particularly high. Every month of reduced heavy drinking is a month of reduced neurotoxic exposure, fewer dangerous falls, better medication efficacy, and potentially slower cognitive decline. The drug exists. The evidence exists. What remains is closing the gap between knowledge and practice.
Conclusion
Naltrexone has been available for more than three decades, costs as little as $25 a month in its oral form, does not require abstinence to begin, and is supported by a substantial body of evidence showing it reduces cravings and heavy drinking. Yet only about 1% of the nearly 30 million Americans with alcohol use disorder have been prescribed it. The reasons — physician unfamiliarity, stigma, cultural attachment to abstinence-only models, and cost barriers for the injectable form — are all solvable problems. None of them are scientific objections to the drug itself.
For families navigating dementia care, alcohol misuse in a loved one is not a side issue. It is a direct threat to brain health that has a pharmacological intervention most people have never been told about. Ask the doctor. Name the drug. Naltrexone will not fix everything, but it is unconscionable that so few people even get the chance to try it.
Frequently Asked Questions
Does naltrexone require a special license for doctors to prescribe it?
No. Unlike buprenorphine for opioid use disorder, which historically required a special waiver, naltrexone can be prescribed by any physician, nurse practitioner, or physician assistant with standard prescribing authority. There is no additional certification or program enrollment required.
Can someone take naltrexone if they are still drinking?
Yes. Unlike some treatment approaches that demand abstinence as a precondition, naltrexone can be started while a person is still consuming alcohol. The medication works by reducing the rewarding effects of drinking, which over time helps many people cut back. This makes it a realistic option for people who are not ready to quit entirely.
Is naltrexone safe for older adults with cognitive impairment?
Naltrexone is generally well tolerated, but it should be discussed with a physician who is aware of all other medications the patient takes. The key contraindication is concurrent use of opioid pain medications — naltrexone will block their effects and can trigger withdrawal. Liver function should also be monitored, as naltrexone is processed by the liver.
How long does someone need to take naltrexone?
There is no fixed duration. Some people take it for several months while establishing new drinking patterns, while others continue it long-term. The decision should be made with a prescribing provider based on individual response and goals. Stopping the medication does not cause withdrawal.
Does insurance cover naltrexone?
Generic oral naltrexone is widely covered and inexpensive even without insurance. Vivitrol, the monthly injection, costs $1,200 to $2,500 without coverage, but approximately 99% of insurance plans reportedly cover it. Prior authorization may be required for the injectable form.
